Current status and progress of medical treatment of high-grade glioma

Abstract

Abstract:

High-grade glioma is characterized by high postoperative recurrence rate， poor efficacy of adjuvant therapy， and direct influence on cognitive function， which eventually leads to a poor prognosis， great harm to patients， and seriously affects the survival and quality of life of patients. In the process of exploring new effective therapeutic strategies in this field， the characteristics of high heterogeneity， high invasiveness and blood-brain barrier limitation have become the main obstacles. At present， the main treatment of glioma is still to remove the glioma lesion as thoroughly as possible through surgery， followed by postoperative medical treatment or combined radiotherapy. However， in the context of high recurrence rate after local treatment such as surgery and radiotherapy， medical treatment is particularly important. In recent years， with the development of molecular pathology， molecular biology， molecular materials engineering， gene sequencing technology and tumor immunology， a series of new and promising techniques for the diagnosis and treatment of brain glioma are emerging. Therefore， it is of profound significance to summarize and analyze the current treatment status， progress and future prospects for further research.

Key words:glioma,high-grade glioma,current situation,progression,medical diagnosis and treatment

摘要：

高级别脑胶质瘤因其术后复发率高、辅助治疗疗效差，并且能直接影响认知功能等特点，导致预后较差，对患者危害巨大，严重影响患者的生存和生活质量。在该领域中探索新的有效的治疗策略过程中，其异质性高、侵袭性强及血脑屏障限制的特点成了最主要的障碍。当下脑胶质瘤的主要治疗方式仍然是先通过手术尽可能彻底地切除胶质瘤病灶，术后辅以内科治疗或者联合放射治疗。然而，在手术及放疗等局部治疗后仍高概率复发的大背景下，内科治疗显得尤为重要。近年来，随着分子病理学、分子生物学、分子材料工程学、基因测序技术及肿瘤免疫学等多学科共同发展，一系列新的、前景广阔、极具潜力的内科诊疗技术涌现出来。对目前高级别脑胶质瘤的治疗现状、进展及未来展望进行归纳、总结和分析将对实施更深层次的研究有着深远的意义。

关键词:脑胶质瘤,高级别脑胶质瘤,现状、进展,内科诊疗

Ran CHEN, Xiang GAO, Shucai ZHANG, Li MA. Current status and progress of medical treatment of high-grade glioma[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(6): 444-451.

陈然, 高翔, 张树才, 马丽. 高级别脑胶质瘤的内科治疗研究现状及进展[J]. betway必威登陆网址（betway.com ）学报, 2023, 44(6): 444-451.

References53

1	Fakhoury KR， Ney DE， Ormond DR， et al. Immunotherapy and radiation for high-grade glioma： a narrative review［J］. Transl Cancer Res， 2021， 10（5）： 2537.
2	Faustino AC， Viani GA， Hamamura AC. Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide［J］. Clinics （Sao Paulo）， 2020， 75： e1553.
3	Xu S， Tang L， Li X， et al. Immunotherapy for glioma： current management and future application［J］. Cancer Lett， 2020， 476： 1.
4	Zhang X， Chen Y， Yao J， et al. β-elemene combined with temozolomide in treatment of brain glioma［J］. Biochem Biophys Rep， 2021， 28： 101144.
5	Ni XR， Guo CC， Yu YJ， et al. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma［J］. Cancer Chemother Pharmacol， 2020， 86（6）： 773.
6	Shaw EG， Wang M， Coons SW， et al. Randomized trial of radiation therapy plus procarbazine， lomustine， and vincristine chemotherapy for supratentorial adult low-grade glioma： initial results of RTOG 9802［J］. J Clin Oncol， 2012， 30（25）： 3065.
7	Lancet Herrlinger U， Tzaridis T， Mack F， et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter （CeTeG/NOA-09）： a randomised， open-label， phase 3 trial［J］. Lancet， 2019， 393（10172）： 678.
8	Ramón Y Cajal S， Sesé M， Capdevila C， et al. Clinical implications of intratumor heterogeneity： challenges and opportunities［J］. J Mol Med （Berl）， 2020， 98（2）： 161.
9	Kummar S， Italiano A， Brose MS， et al. Diagnosis and management of TRK fusion cancer［J］. Am J Manag Care， 2022， 28（2 ）： S15.
10	Doz F， Van Tilburg CM， Geoerger B， et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors［J］. Neuro Oncol， 2022， 24（6）： 997.
11	Yamashita S， Yokogami K， Matsumoto F， et al. MGMT promoter methylation in patients with glioblastoma： is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay？［J］. J Neurosurg， 2018， 130（3）： 780.
12	Palma A， Grande S， Ricci-Vitiani L， et al. Different mechanisms underlie the metabolic response of GBM stem-like cells to ionizing radiation： biological and MRS studies on effects of photons and carbon ions［J］. Int J Mol Sci， 2020， 21（14）： 5167.
13	Wen PY， De Groot JF， Battiste JD， et al. Escalation portion of phase Ⅱ study to evaluate the safety， pharmacokinetics， and clinical activity of the PI3K/mTOR inhibitor paxalisib （GDC-0084） in glioblastoma （GBM） with unmethylated O6-methylguanine-methyltransferase （MGMT） promotor status［J］. J Clin Oncol， 2020， 38（）： 2550.
14	Subbiah V， Puzanov I， Blay JY， et al. Pan-cancer efficacy of vemurafenib inBRAF^V600-mutant non-melanoma cancers［J］. Cancer Discov， 2020， 10（5）： 657.
15	Śledzińska P， Bebyn MG， Furtak J， et al. Prognostic and predictive biomarkers in gliomas［J］. Int J Mol Sci， 2021， 22（19）： 10373.
16	Vuong HG， Altibi AMA， Duong UNP， et al. TERT promoter mutation and its interaction with IDH mutations in glioma： combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-a meta-analysis of aggregate data［J］. Crit Rev Oncol Hematol， 2017， 120： 1.
17	Bai H， Bai S， Li X， et al. Establishment and validation of the detection of TERT promoter mutations by human gliomas U251 cell lines［J］. Biomed Res Int， 2021， 2021： 3271395.
18	Binder DC， Ladomersky E， Lenzen A， et al. Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma［J］. Transl Cancer Res， 2018， 7（）： S510.
19	Wick W， Gorlia T， Bendszus M， et al. Lomustine and bevacizumab in progressive glioblastoma［J］. N Engl J Med， 2017， 377（20）： 1954.
20	Lombardi G， De Salvo GL， Brandes AA， et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma （REGOMA）： a multicentre， open-label， randomised， controlled， phase 2 trial［J］. Lancet Oncol， 2019， 20（1）： 110.
21	Louis DN， Perry A， Wesseling P， et al. The 2021 WHO classification of tumors of the central nervous system： a summary［J］. Neuro Oncol， 2021， 23（8）： 1231.
22	Tateishi K， Wakimoto H， Iafrate AJ， et al. Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion［J］. Cancer Cell， 2015， 28（6）： 773.
23	Zhang ZY， Chan AK， Ding XJ， et al. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade Ⅱ and Ⅲ diffuse gliomas［J］. Oncotarget， 2015， 6（28）： 24871.
24	De La Fuente MI， Colman H， Rosenthal M， et al. A phase Ⅰb/Ⅱ study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas： safety and efficacy as single agent and in combination with azacitidine［J］. J Clin Oncol， 2020， 38（）： 2505.
25	季玉陈，湛允波，刘献志，等. IDH、TERT及1p/19q对间变性少突胶质瘤患者预后的影响［J］. 中华医学杂志， 2019， 99（25）： 1959.
26	Flavahan WA， Drier Y， Liau BB， et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas［J］. Nature， 2016， 529（7584）： 110.
27	Mittal S， Pradhan S， Srivastava T. Recent advances in targeted therapy for glioblastoma［J］. Expert Rev Neurother， 2015， 15（8）： 935.
28	Bersanelli M， Buti S. From targeting the tumor to targeting the immune system： transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis［J］. World J Clin Oncol， 2017， 8（1）： 37.
29	Arrieta VA， Iwamoto F， Lukas RV， et al. Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma？［J］. J Neurosurg， 2019， 132（5）： 1667.
30	Reardon DA， Brandes AA， Omuro A， et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma： the CheckMate 143 phase 3 randomized clinical trial［J］. JAMA Oncol， 2020， 6（7）： 1003.
31	Weathers SPS， Kamiya-Matsuoka C， Harrison RA， et al. Phase Ⅰ/Ⅱ study to evaluate the safety and clinical efficacy of atezolizumab （atezo； aPDL1） in combination with temozolomide （TMZ） and radiation in patients with newly diagnosed glioblastoma （GBM）［J］. J Clin Oncol， 2020， 38（）： 2511.
32	Fong B， Jin R， Wang X， et al. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells， before and after DC vaccination， can predict survival in GBM patients［J］. PLoS One， 2012， 7（4）： e32614.
33	Yao Y， Wang X， Jin K， et al. B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells［J］. J Neurooncol， 2008， 89（2）： 121.
34	Jeon H， Vigdorovich V， Garrett-Thomson SC， et al. Structure and cancer immunotherapy of the B7 family member B7x［J］. Cell Rep， 2014， 9（3）： 1089.
35	Das M， Zhu C， Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity［J］. Immunol Rev， 2017， 276（1）： 97.
36	Hanihara M， Kawataki T， Oh-Oka K， et al. Synergistic antitumor effect with indoleamine 2，3-dioxygenase inhibition and temozolomide in a murine glioma model［J］. J Neurosurg， 2016， 124（6）： 1594.
37	Li G， Wang Z， Zhang C， et al. Molecular and clinical characterization of TIM-3 in glioma through 1，024 samples［J］. Oncoimmunology， 2017， 6（8）： e1328339.
38	Keskin DB， Anandappa AJ， Sun J， et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial［J］. Nature， 2019， 565（7738）： 234.
39	Hilf N， Kuttruff-Coqui S， Frenzel K， et al. Actively personalized vaccination trial for newly diagnosed glioblastoma［J］. Nature， 2019， 565（7738）： 240.
40	Felsberg J， Hentschel B， Kaulich K， et al. Epidermal growth factor receptor variant Ⅲ （EGFRvⅢ） positivity inEGFR-amplified glioblastomas： prognostic role and comparison between primary and recurrent tumors［J］. Clin Cancer Res， 2017， 23（22）： 6846.
41	Liau LM， Ashkan K， Tran DD， et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma［J］. J Transl Med， 2018， 16（1）： 142.
42	Yao Y， Luo F， Tang C， et al. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma： an exploratory randomized phase Ⅱ clinical trial［J］. Cancer Immunol Immunother， 2018， 67（11）： 1777.
43	Balaji E V， Pai KSR. Stem cells delivered oncolytic virus to destroy formidable brain tumor［J］. Stem Cell Rev Rep， 2022， 18（1）： 395.
44	Martinez-Quintanilla J， Seah I， Chua M， et al. Oncolytic viruses： overcoming translational challenges［J］. J Clin Invest， 2019， 129（4）： 1407.
45	King JL， Benhabbour SR. Glioblastoma multiforme-a look at the past and a glance at the future［J］. Pharmaceutics， 2021， 13（7）： 1053.
46	Saha D， Martuza RL， Rabkin SD. Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade［J］. Cancer Cell， 2017， 32（2）： 253.
47	Taguchi S， Fukuhara H， Todo T. Oncolytic virus therapy in Japan： progress in clinical trials and future perspectives［J］. Jpn J Clin Oncol， 2019， 49（3）： 201.
48	Suryawanshi YR， Schulze AJ. Oncolytic viruses for malignant glioma： on the verge of success？［J］. Viruses， 2021， 13（7）： 1294.
49	Tamura K， Aoyagi M， Ando N， et al. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy［J］. J Neurosurg， 2013， 119（5）： 1145.
50	Alphandéry E. Nano-therapies for glioblastoma treatment［J］. Cancers （Basel）， 2020， 12（1）： 242.
51	Wu W， Klockow JL， Mohanty S， et al. Theranostic nanoparticles enhance the response of glioblastomas to radiation［J］. Nanotheranostics， 2019， 3（4）： 299.
52	Ruiz-Garcia H， Ramirez-Loera C， Malouff TD， et al. Novel strategies for nanoparticle-based radiosensitization in glioblastoma［J］. Int J Mol Sci， 2021， 22（18）： 9673.
53	Miller MA， Chandra R， Cuccarese MF， et al. Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts［J］. Sci Transl Med， 2017， 9（392）： eaal0225.

[1]	Guimi SI, Changping SHAN.The progress of exosomal non-coding RNA in triple-negative breast cancer[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(6): 461-465.
[2]	Cheng WANG, Jie MENG, Li ZHU, Danyan LI.Multiphase enhancement CT features of bladder paraganglioma[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(6): 439-441.
[3]	Junping Huang, Zhiyu Zhou, Changji Xie, Huan Lan, Guang Li.The effect of volume rotation intensity-modulated radiotherapy （VMRT） in patients with glioma[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(8): 598-601.
[4]	Liu Jie, Li Xuanzong, Yu Jinming.Research on the progress in radiotherapy of lung cancer in 2020[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(5): 321-326.
[5]	Youyu Li, Nana Gan.Investigation on deciduous tooth caries of children in a private kindergarten in Chuzhou and analysis of its influencing factors[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(11): 871-875.